vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $86.8M, roughly 1.3× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 9.0%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.4%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
BY vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $86.8M |
| Net Profit | $37.6M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 33.4% | — |
| Revenue YoY | 9.0% | 17.7% |
| Net Profit YoY | 33.0% | — |
| EPS (diluted) | $0.83 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $86.8M | ||
| Q3 25 | $115.7M | $67.5M | ||
| Q2 25 | $110.5M | $60.0M | ||
| Q1 25 | $103.1M | $49.3M | ||
| Q4 24 | $104.7M | $73.7M | ||
| Q3 24 | $101.8M | $58.6M | ||
| Q2 24 | $99.4M | $31.1M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | — | ||
| Q3 25 | $37.2M | $-91.3M | ||
| Q2 25 | $30.1M | $-111.7M | ||
| Q1 25 | $28.2M | $-116.2M | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $30.3M | $-83.5M | ||
| Q2 24 | $29.7M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | -84.7% | ||
| Q3 25 | 43.1% | -140.7% | ||
| Q2 25 | 35.2% | -189.8% | ||
| Q1 25 | 36.4% | -245.8% | ||
| Q4 24 | 38.6% | -117.5% | ||
| Q3 24 | 39.3% | -152.1% | ||
| Q2 24 | 40.4% | -327.6% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | — | ||
| Q3 25 | 32.1% | -135.3% | ||
| Q2 25 | 27.2% | -186.2% | ||
| Q1 25 | 27.4% | -235.5% | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 29.8% | -142.7% | ||
| Q2 24 | 29.9% | -312.2% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | — | ||
| Q3 25 | $0.82 | — | ||
| Q2 25 | $0.66 | $-0.33 | ||
| Q1 25 | $0.64 | $-0.36 | ||
| Q4 24 | $0.68 | $-0.24 | ||
| Q3 24 | $0.69 | $-0.28 | ||
| Q2 24 | $0.68 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $698.6M |
| Total Assets | $9.9B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $297.0M | ||
| Q3 25 | $259.0M | $300.8M | ||
| Q2 25 | $218.3M | $301.2M | ||
| Q1 25 | $421.3M | $359.7M | ||
| Q4 24 | $563.1M | $323.8M | ||
| Q3 24 | $452.6M | $397.5M | ||
| Q2 24 | $730.5M | $412.5M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $698.6M | ||
| Q3 25 | $1.2B | $702.3M | ||
| Q2 25 | $1.2B | $698.5M | ||
| Q1 25 | $1.1B | $767.9M | ||
| Q4 24 | $1.1B | $710.4M | ||
| Q3 24 | $1.1B | $773.5M | ||
| Q2 24 | $1.0B | $768.5M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $913.2M | ||
| Q3 25 | $9.8B | $904.9M | ||
| Q2 25 | $9.7B | $907.4M | ||
| Q1 25 | $9.6B | $966.7M | ||
| Q4 24 | $9.5B | $910.4M | ||
| Q3 24 | $9.4B | $991.1M | ||
| Q2 24 | $9.6B | $964.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $-52.6M | ||
| Q3 25 | $38.3M | $-78.7M | ||
| Q2 25 | $16.3M | $-67.4M | ||
| Q1 25 | $27.1M | $-103.7M | ||
| Q4 24 | $175.2M | $-73.3M | ||
| Q3 24 | $19.8M | $-59.0M | ||
| Q2 24 | $40.1M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $-61.9M | ||
| Q3 25 | $38.0M | $-89.5M | ||
| Q2 25 | $15.2M | $-74.9M | ||
| Q1 25 | $25.0M | $-109.9M | ||
| Q4 24 | $171.2M | $-77.5M | ||
| Q3 24 | $19.1M | $-61.3M | ||
| Q2 24 | $39.4M | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | -71.3% | ||
| Q3 25 | 32.8% | -132.7% | ||
| Q2 25 | 13.7% | -124.9% | ||
| Q1 25 | 24.3% | -222.8% | ||
| Q4 24 | 163.5% | -105.1% | ||
| Q3 24 | 18.8% | -104.6% | ||
| Q2 24 | 39.7% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 10.7% | ||
| Q3 25 | 0.3% | 16.1% | ||
| Q2 25 | 1.0% | 12.4% | ||
| Q1 25 | 2.0% | 12.6% | ||
| Q4 24 | 3.8% | 5.7% | ||
| Q3 24 | 0.6% | 3.9% | ||
| Q2 24 | 0.7% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BY
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
